Intra-cellular Therapies, INC

Intra-Cellular Therapies' stockholders have approved the merger agreement with Johnson & Johnson, paving the way for the company to become a wholly-owned subsidiary.

Intra-Cellular Therapies supplements its proxy statement related to the proposed merger with Johnson & Johnson, addressing stockholder lawsuits alleging disclosure deficiencies.

Intra-Cellular Therapies' merger with Johnson & Johnson progresses as the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 expires.

Intra-Cellular Therapies announces a 47% increase in CAPLYTA net product sales for 2024, reaching $680.5 million, and the FDA's acceptance of its sNDA for adjunctive treatment of major depressive disorder (MDD).

Johnson & Johnson will acquire Intra-Cellular Therapies for $132 per share in cash, totaling approximately $14.6 billion, to expand its neuroscience offerings.

Intra-Cellular Therapies has reached a settlement with Sandoz, allowing Sandoz to sell generic versions of CAPLYTA starting July 1, 2040, or earlier under certain conditions.

Intra-Cellular Therapies reports a 39% increase in product sales for the third quarter of 2024, driven by continued growth in CAPLYTA prescriptions.

Intra-Cellular Therapies reports a 46% increase in product sales for the second quarter of 2024 and positive results from Phase 3 trials for lumateperone in major depressive disorder.

Intra-Cellular Therapies saw a 53% increase in product sales in the first quarter of 2024, while also progressing its clinical trials for various neurological and psychiatric disorders.

Intra-Cellular Therapies files an amendment to its 2024 annual report to include previously omitted information on directors, executive compensation, and corporate governance, amidst an ongoing merger agreement with Johnson & Johnson.

Intra-Cellular Therapies (ITCI) has entered into a definitive agreement to be acquired by Johnson & Johnson for $132 per share in cash, valuing the company at approximately $14.6 billion.

Intra-Cellular Therapies, Inc. outlines its common stock structure, anti-takeover provisions, and corporate governance policies in its latest 10-K filing.

Director Eduardo Rene Salas reports the disposal of Intra-Cellular Therapies shares and cancellation of stock options following the company's merger with Johnson & Johnson, where shareholders received $132 per share.

Director Riggs Rory B reports the disposal of common stock and stock options in Intra-Cellular Therapies following the company's merger with Johnson & Johnson on April 2, 2025.

Michael Halstead, President of Intra-Cellular Therapies, reports the disposal of shares and derivative securities following the merger with Johnson & Johnson, where each share was converted into $132 in cash.

Director Robert L. Van Nostrand reports the disposal of Intra-Cellular Therapies shares and derivative securities following the completion of the merger with Johnson & Johnson on April 2, 2025.

Mark Neumann, EVP and Chief Commercial Officer of Intra-Cellular Therapies, Inc., reports the disposal of shares and derivative securities following the company's merger with Johnson & Johnson.

Joel S. Marcus reports the disposition of Intra-Cellular Therapies shares and derivative securities following the company's merger with a Johnson & Johnson subsidiary at a price of $132 per share.

Intra-Cellular Therapies (ITI) stockholders are set to vote on a proposed merger agreement with Johnson & Johnson, where ITI would become a wholly-owned subsidiary of J&J at $132 per share.

Intra-Cellular Therapies (ITCI) has announced a definitive agreement to be acquired by Johnson & Johnson, pending shareholder and regulatory approvals.

Johnson & Johnson will acquire Intra-Cellular Therapies for $132.00 per share in cash, totaling approximately $14.6 billion, to strengthen its neuroscience leadership and add CAPLYTA to its portfolio.

Intra-Cellular Therapies, Inc. will hold its annual stockholder meeting virtually on June 14, 2024, to vote on key proposals including the election of a director, approval of an equity incentive plan amendment, ratification of the auditor, and an advisory vote on executive compensation.

Intra-Cellular Therapies is asking stockholders to approve an amendment and restatement of its 2018 Equity Incentive Plan to increase the number of shares available for issuance.